Key Finding
Electroacupuncture at ST 25 and ST 37 significantly reduced visceral hypersensitivity and anxiety-like behavior in IBS-D rats by downregulating colonic NGF, TrkA, and TRPV1 protein expression.
If you've ever dealt with the unpredictable cramping, urgency, and frequent loose stools of diarrhea-predominant irritable bowel syndrome (IBS-D), you know how much it can take over your life — and your mood. A new animal study published in Chinese Acupuncture & Moxibustion explored whether electroacupuncture could help, and the results are encouraging.
Researchers worked with rats that were given IBS-D and then treated with electroacupuncture at two well-known acupuncture points: Tianshu (ST 25), located near the navel, and Shangjuxu (ST 37), on the lower leg. These points have long been used in Traditional Chinese Medicine to support digestive health. The rats received 20-minute electroacupuncture sessions daily for one week.
The results were striking. Compared to untreated IBS-D rats, the electroacupuncture group showed significant improvements across the board. Their stool water content decreased, meaning less diarrhea. Their gut pain sensitivity dropped, suggesting less cramping and discomfort. They also showed fewer signs of anxiety and depression-like behavior — something many IBS sufferers will recognize as a very real part of the condition.
Perhaps most interesting was what happened at the molecular level. The electroacupuncture treatment lowered levels of three proteins in the colon — NGF, TrkA, and TRPV1 — that are involved in how the gut senses pain and sends distress signals to the brain. By dialing down these proteins, electroacupuncture appears to calm an oversensitive gut-brain connection.
These results were comparable to those seen with a standard Western medication used for IBS, pinaverium bromide.
While this was an animal study and more human research is needed, it adds to a growing body of evidence supporting acupuncture as a meaningful option for IBS management. If you're curious about trying electroacupuncture for IBS, seek out a licensed, qualified acupuncture practitioner with experience in digestive health.
This controlled animal study (n=36 male SD rats, 4 groups: blank, model, electroacupuncture, and pinaverium bromide) investigated the mechanisms by which electroacupuncture (EA) at ST 25 and ST 37 affects diarrhea-predominant IBS (IBS-D), modeled via DNBS enema combined with chronic restraint stress. EA was delivered at 2 Hz/100 Hz disperse-dense wave, 20 min/day for 7 days. Post-intervention, the EA group demonstrated statistically significant reductions in fecal water content, visceral hypersensitivity (AWR latency lengthened, contraction wave frequency reduced), and anxiety-like behavior (elevated plus maze OT% increased) compared to the model group (P<0.05). Immunohistochemistry and Western blot analysis revealed significant downregulation of colonic NGF, TrkA, and TRPV1 protein expression in the EA group, mirroring outcomes in the western medication group. These findings suggest EA at ST 25/ST 37 attenuates visceral hypersensitivity in IBS-D via modulation of the NGF-TrkA-TRPV1 nociceptive signaling pathway, with concurrent improvement in anxiety-depressive comorbidity.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 A randomized controlled pilot trial is underway to evaluate whether electroacupuncture combined with standard medication can address both tinnitus and hearing outcomes in patients with idiopathic sudden sensorineural hearing loss, an approach largely overlooked by current treatment protocols.
📌 Transcutaneous electrical stimulation at Zusanli (ST36) upregulated neurotrophic factors BDNF and NGF, while Neiguan (PC6) stimulation elevated NPY and sympathoadrenal markers, demonstrating distinct point-specific effects on neuroimmune modulation and postoperative pain outcomes in lumbar disc herniation surgery patients.
📌 Electroacupuncture at GV20, ST25, and BL25 reduced both visceral hypersensitivity and negative emotions in an IBS-D model by suppressing overactivated PVN CRFergic neurons and downregulating the downstream colonic CRF-R1/mast cell/TRPV1 inflammatory pathway.